Scott Galloway said GLP-1 drugs could solve many of the health and economic problems facing the U.S. if policy and pricing barriers are removed [1].
The argument highlights a potential shift in public health strategy. If medications like Ozempic and Wegovy become widely accessible, the resulting decrease in obesity and diabetes could lower the overall cost of national healthcare [2].
Galloway, a professor at the NYU Stern School of Business and public speaker, said these medications are a "silver bullet for America's woes, if we're not stupid enough to get in the way" [1]. He said these drugs can cut obesity rates and lower the incidence of diabetes [2].
Despite the clinical potential, Galloway said regulatory inertia and high costs are primary obstacles to widespread adoption. He cited the typical monthly cost of Wegovy in the U.S. as $1,000 [1]. This price point creates a significant barrier for many citizens who would otherwise benefit from the treatment.
Clinical data supports the efficacy of these medications. Trials of GLP-1 drugs have shown an average weight loss of 15% of body weight [2]. Such a reduction in weight often correlates with improved metabolic health, and a lower risk of chronic disease.
Galloway said the drugs can "ultimately reduce the nation's healthcare spending" [2]. However, he suggests that this economic benefit will only be realized if the government and insurance providers address the current pricing structures that limit access to the general population.
“"GLP‑1 drugs are a silver bullet for America's woes, if we're not stupid enough to get in the way."”
The debate over GLP-1 drugs is shifting from clinical efficacy to economic accessibility. By framing obesity as a treatable medical condition rather than a behavioral failure, Galloway suggests that the U.S. could see a systemic reduction in chronic disease costs, provided the high cost of entry is lowered through policy intervention.
